Health

J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the upcoming 2022 World Conference on Lung Cancer in Vienna, Austria

SEOUL, South Korea, June 14, 2022 /PRNewswire/ -- J INTS BIO announced that it will be presenting the preclinical results of its NSCLC candidate 'JIN-A02' at the upcoming 2022 IASLC World Conference on Lung Cancer, to be held inVienna, Austria from 6th to 9th August.

2022-06-14 22:00 1058

Zhimeng Biopharma will report positive phase 1b trial results on its HBV capsid inhibitor ZM-H1505R in the upcoming International Liver Congress

SHANGHAI, June 14, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma announces that it will report the positive results obtained from a phase1b study on its HBV capsid inhibitor ZM-H1505R in the International Liver Congress inJune 22-26, 2022 (the EASL meeting).  The recently completed phase 1b stu...

2022-06-14 20:00 1153

Zepp Health Corporation to Hold Annual General Meeting on July 5, 2022

BEIJING, June 14, 2022 /PRNewswire/ -- Zepp Health Corporation, ("Zepp Health", the "Company" or "we") (NYSE: ZEPP), a cloud-based healthcare services provider with world-leading smart wearable technology, today announced that it will hold its annual general meeting of shareholders (the "AGM") at...

2022-06-14 20:00 3580

United Imaging Shows Up Big, Differently

Focusing squarely on its Equal Healthcare for All™ mission, the company had its flagship digital PET/CT driven across the border on a trailer to SNMMI 2022. HOUSTON, June 14, 2022 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment,...

2022-06-14 20:00 1425

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, June. 14, 2022  /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of ...

2022-06-14 20:00 1300

Telix and Invicro Advance AI Partnership

MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to develop an artificial...

2022-06-14 19:00 2006

Kintor Pharma and Etana's Collaboration on Pruxelutamide's COVID-19 Project Awarded with Belt and Road Innovation Project and Fund Support from the Science and Technology Department of Jiangsu Province

SUZHOU, China, June 14, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that its "clinical trial cooperative research and development and ov...

2022-06-14 12:35 1965

Good News from Taiwan Participants in BIO 2022 - Pharmasaga and PrecisemAb Make It to the Start-Up Stadium Finalists Defeating Hundred Teams

TAIPEI, June 13, 2022 /PRNewswire/ -- As the post-pandemic era approaches, the biomedical industry has become a strategic domain of focal emphasis inTaiwan and would be the critical impetus for the next wave of growth. In order to step up international connection and strive for business opportuni...

2022-06-14 00:00 2030

META Pharmaceuticals, a pioneer biotech in immune-metabolism, raised 15M USD to accelerate its pipeline development

SHENZHEN, China, June 13, 2022 /PRNewswire/ -- Today, META Pharmaceuticals, China's first immunometabolism-based small-molecule drug discovery company, announced two consecutive Seed and Pre-A funding rounds totaling15 million USD. Investors include Forcefield Ventures, XtalPi Inc., IMO Ventures,...

2022-06-13 20:00 2112

Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network

MELBOURNE, Australia and INDIANAPOLIS, June 13, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), is now available at selected pharmacies in ...

2022-06-13 19:11 2061

Curocell announced impressive CR rate in Phase 1 study with anbal-cel, the next generation CD19 CAR-T integrated OVIS™ platform

-  82% ORR (9 of 11 patients) and 82% (9 of 11 patients) CR rate documented after  anbal-cel treatment to the patients in relapsed/refractory large B-cell lymphoma -  2 out of 3 patients dosed with 2x105 cells/kg of anbal-cel lasting the complete response for more than 12 months -  Well tolerat...

2022-06-13 19:00 1797

POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING

SYDNEY, June 13, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data regarding the activity of paxalisib in two forms of childhood brain cancer with poor prognosis and limited t...

2022-06-13 19:00 4154

Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

* In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history GAITHERSBURG, Md., June 13, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-...

2022-06-13 19:00 2209

Zhongchao Inc. Announces its MDMOOC Platform Launched Disease Prevention and Distribution Quality Management Course

SHANGHAI, June 13, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today ...

2022-06-13 18:30 1673

DSM and Firmenich confirm leadership team for proposed combined company DSM-Firmenich

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. NOT FOR GENERAL RELEASE INTHE UNITED STATES – SEE FURTHER INFORMATION ...

2022-06-13 13:00 3843

Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES™ Molecular Glue KPG-818 in Systemic Lupus Erythematosus

SHANGHAI, June 12, 2022 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based inShanghai, China, announced today that the first patient has been dosed in the Company's US Phase IIa clinical trial of KPG-818, an orally bioavailable NeoMIDESTM molecular glue, for the treatment o...

2022-06-13 09:00 1712

EHA 2022 | Ascentage Pharma Releases Encouraging Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

SUZHOU, China, and ROCKVILLE, MD, June 12, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released results from a Phase I study ...

2022-06-13 07:45 3789

Guojun Lang, CEO of Sanyou: New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets

SHANGHAI, June 10, 2022 /PRNewswire/ -- Recently, Sanyou Biopharmaceuticals officially launched its independently developed Super-Trillion Antibody Libraries (STAL), and the concomitant innovative antibody drug discovery platform. Established by Sanyou after seven years of continuous innovation a...

2022-06-11 08:00 6017

Telix and RefleXion Expand Partnership for Prostate Cancer Treatment

MELBOURNE, Australia and INDIANAPOLIS, June 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) today announced the signing of a co-development and commercialisation agreement, to expand the use ...

2022-06-10 19:00 2769

Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350

CHENGDU, China, June 10, 2022 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced today that the first patient has been dosed in the Phase I trial of CM350. CM350 is a GPC3xCD3 bispecific antibody developed by the Company for the treatment of solid tumors. The phase I trial is being conduc...

2022-06-10 18:42 2032
1 ... 141142143144145146147 ... 273